James R. Ravitz

Subscribe to James R. Ravitz's Posts
James (Jamie) Ravitz is the co-head of the Firm’s Life Sciences industry practice and head of McDermott’s Food and Drug Administration (FDA) practice. He works alongside clients across the entire spectrum of life sciences and healthcare law, including regulatory counsel, compliance, and investigations and government enforcement. He is particularly focused on Food and Drug Administration (FDA) regulatory counseling. Jamie works in partnership with companies and investors across the complete ecosystem of FDA-regulated products—drugs, devices, health technologies, biologics, food, cosmetics and cannabis— to help them achieve their business goals.Read James R. Ravitz's full bio.

DOJ Proposes to Reschedule Marijuana (Cannabis) to Schedule III


By , , , , and on Jun 3, 2024
Posted In Cannabis, Food Safety and FDA, Hemp-Derived Beverages, THC Beverages

On May 21, 2024, the US Department of Justice (DOJ) published the highly anticipated notice of proposed rulemaking (NPRM) to reschedule marijuana (cannabis) from a Schedule I controlled substance to Schedule III, taking the first step to easing federal restrictions on cannabis and potentially opening up the door for further cannabis research and development. This regulatory change...

Continue Reading



BLOG EDITOR

STAY CONNECTED

TOPICS

ARCHIVES